潘慧超,伍旭升,吴献豪,万千里,陈守涛,陈小虎,刘宝宏,蒋利

• 1:上海市同仁医院心内科

摘要(Abstract)：

目的探讨超高龄老年患者接受冠状动脉介入诊疗术[冠状动脉造影(CAG)、经皮冠状动脉介入治疗(PCI)]后发生对比剂肾病(CIN)的相关危险因素。方法选择2012年11月至2015年5月在上海市同仁医院心内科接受CAG、PCI的超高龄(≥80岁)患者303例,根据术后48 h内的血清肌酸酐(肌酐)水平变化分为CIN组和非CIN组,并对相关危险因素进行分析。结果 303例超高龄患者中,发生CIN者共31例(10.2%,CIN组)。两组患者的高血压分级、急诊/择期手术、冠状动脉病变支数及程度、死亡率、尿微量白蛋白等资料比较,差异均有统计学意义(均P<0.05)。多因素Logistic回归分析显示,超高龄患者的高血压分级、急诊/择期手术、病变程度、估算的肾小球滤过率(e GFR)和尿微量白蛋白是CIN发生的危险因素(均P<0.05)。结论高血压分级、急诊/择期手术、病变程度、e GFR和尿微量白蛋白是超高龄患者CAG或者PCI后CIN发生的危险因素,超高龄患者应当加强围术期综合因素管理,有效预防对比剂肾病。

关键词(KeyWords)： 对比剂肾病;危险因素;冠状动脉造影;经皮冠状动脉介入治疗

Abstract:

Keywords:

基金项目(Foundation): 上海卫计委科研课题(20124Y02001)

作者(Author): 潘慧超,伍旭升,吴献豪,万千里,陈守涛,陈小虎,刘宝宏,蒋利

参考文献(References)：

• [1]陈韵岱,陈纪言,傅国胜,等.碘对比剂血管造影应用相关不良反应中国专家共识.中国介入心脏病学杂志,2014,22:341-348.
• [2]Levine GN,Bates ER,Blankenship JC,et al.2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention:executive summary:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.Catheter Cardiovasc Interv,2012,79:453-495.
• [3]Gao YM,Li D,Cheng H,et al.Derivation and validation of a risk score for contrastinduced nephropathy after cardiac catheterization in Chinese patients.Clin Exp Nephrol,2014,18:892-898.
• [4]刘远辉,谭宁,刘勇,等.高尿酸血症与慢性肾脏疾病患者经皮冠状动脉介入治疗后对比剂肾病的相关性.中华心血管病杂志,2013,41:740-743.
• [5]Toso A,Leoncini M,Maioli M,et al.Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal dysfunction.J Cardiovasc Med,2011,12:318-321.
• [6]王丛笑,郝菁华,叶远红.非离子型对比剂对老年肿瘤患者肾功能影响临床分析.医学影像学杂志,2009,19:561-563.
• [7]刘润梅,夏云峰,殷亚晞,等.非离子造影剂对老年冠状动脉造影患者肾功能的影响.中华老年心脑血管病杂志,2006,8:180-183.
• [8]Shalansky SJ,Vu T,Pate GE,et al.N-acetylcysteine for prevention of radiographic contrastmaterial-induced nephropathy:isthe intravenous route best?Pharmacotherapy,2005,25:1095-1103.
• [9]李玉兰,周旭晨,黄榕翀.行PCI术的老年患者发生对比剂肾病危险因素分析.中国现代医药杂志,2009,11:40-42.
• [10]Schrier RW,Wang W,Poole B,et al.Acute renal failure:definitions,diagnosis,pathogenesis,and therapy.J Clin Invest,2004,114:5-14.
• [11]Bidani AK,Griffin KA.Long-term renal consequences of hypertension for normal and diseased kidneys.Curr Opin Nephrol Hypertens,2002,11:73-80.
• [12]Krummel T,Bazin D,Faller AL,et al.Hypertensive nephrosclerosis.Presse Med,2012,41:116-124.
• [13]Bakris GL.Micro albuminuria:what is it?Why is it important?What should be done about it?J Clin Hypertens(Greenwich),2001,3:99-102.
• [14]李明洲.高血压患者微量白蛋白尿的阳性率与相关因素.中国心血管杂志,1998,6:405.
• [15]Stehouwer CD,Smulders YM.Micro albuminuria and risk for cardiovascular disease:analysis of potential mechanisms.J Am Soc Nephrol,2006,17:2106-2111.
• [16]郑华,屠燕,马立勤.冠心病患者经皮冠状动脉介入术后并发造影剂肾病的危险因素分析及防治策略探讨.南方医科大学学报,2011,31:1273-1276.